Trung Huynh
Stock Analyst at UBS
(2.45)
# 189
Out of 4,869 analysts
45
Total ratings
63.33%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $633 → $560 | $509.72 | +9.86% | 3 | Jun 5, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $5.15 | +540.78% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $20.50 | +85.41% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $102.68 | +6.16% | 5 | May 9, 2025 | |
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $289.33 | +8.87% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $762.73 | +37.66% | 8 | May 2, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $23.97 | +4.30% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.86 | +15.24% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.79 | +291.06% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.07 | +323.45% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $149.79 | +16.83% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $79.06 | +59.37% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $185.30 | -8.26% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.77 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $633 → $560
Current: $509.72
Upside: +9.86%
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $5.15
Upside: +540.78%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $20.50
Upside: +85.41%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $102.68
Upside: +6.16%
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $289.33
Upside: +8.87%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $762.73
Upside: +37.66%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $23.97
Upside: +4.30%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.86
Upside: +15.24%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.79
Upside: +291.06%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.07
Upside: +323.45%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $149.79
Upside: +16.83%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $79.06
Upside: +59.37%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $185.30
Upside: -8.26%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.77
Upside: -